# US 11,111,282 B2 · Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,282 B2
- Document ID: US11111282B2
- Status: Granted
- Kind: B2
- Application number: 16/270,365
- Filed: 2019-02-07
- Published: 2019-07-25
- Granted: 2021-09-07
- Earliest claimed: 2015-02-27
- Assignees: The University of Vermont and State Agriculture College
- Applicants: The University of Vermont and State Agriculture College
- Inventors: Jeffrey Spees
- Web page: https://patentgrep.com/patent/US11111282B2

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/47: from mammals
- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.

## Claims

### Claim 1

A method for reducing vascular endothelial cell damage or vascular endothelial cell death following myocardial ischemia with reperfusion in a subject, the method comprising administering to the subject intra-arterially a composition comprising an HGF/IgG complex at the time of reperfusion, wherein the HGF/IgG complex does not comprise an antibody-antigen interaction, thereby reducing vascular endothelial cell damage or vascular endothelial cell death following myocardial ischemia with reperfusion relative to a reference.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method increases vascular integrity in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method reduces vascular permeability.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell death occurs during hypoxia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the step of administering results in activating receptor-like tyrosine kinase (RYK) by phosphorylation.